Essure Revenue and Competitors
Estimated Revenue & Valuation
- Essure's estimated annual revenue is currently $21.1M per year.
- Essure's estimated revenue per employee is $251,000
Employee Data
- Essure has 84 Employees.
- Essure grew their employee count by 18% last year.
Essure's People
Name | Title | Email/Phone |
---|
Essure Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Essure?
Conceptus, Inc. is a leader in the design, development, and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure, which was FDA approved in 2002 and is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay. Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with nearly 500,000 women worldwide having undergone the Essure procedure.
keywords:N/AN/A
Total Funding
84
Number of Employees
$21.1M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Essure News
This method, called Essure and formerly marketed by Bayer, received approval by the US Food and Drug Administration in 2002.
Hysteroscopic sterilization uses a medical device known by the trade name Essure to block the fallopian tubes. The implanted metal coils...
The U.S. lawsuit related to Bayer's Essure, a permanent device, resulted in a $1.6 billion out-of-court settlement in 2020.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.5M | 84 | 8% | N/A |
#2 | $12.2M | 84 | -54% | N/A |
#3 | $27.7M | 84 | 1% | N/A |
#4 | $27.3M | 84 | 5% | N/A |
#5 | $33.6M | 84 | -6% | N/A |